Neurogene Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Neurogene
NGNE Stock   18.99  0.68  3.71%   
Neurogene's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Neurogene's valuation are provided below:
Gross Profit
-69.7 M
Market Capitalization
294.2 M
Enterprise Value Revenue
480.9433
Earnings Share
(4.10)
There are over one hundred nineteen available fundamental ratios for Neurogene, which can be analyzed over time and compared to other ratios. Investors should ensure to check all of Neurogene's last-minute performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. As of January 23, 2026, Market Cap is expected to decline to about 438.7 M. In addition to that, Enterprise Value is expected to decline to about 303.1 M

Neurogene Total Revenue

790,875

Check Neurogene financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurogene's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.9 M, Other Operating Expenses of 100.9 M or Research Development of 73.6 M, as well as many indicators such as Price To Sales Ratio of 410, Dividend Yield of 0.0 or PTB Ratio of 1.41. Neurogene financial statements analysis is a perfect complement when working with Neurogene Valuation or Volatility modules.
  
Build AI portfolio with Neurogene Stock
Check out the analysis of Neurogene Correlation against competitors.
For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.

Neurogene Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets405.4 M386.1 M146.8 M
Slightly volatile
Other Current Liabilities6.4 M12.4 M5.9 M
Slightly volatile
Total Current Liabilities18.3 M17.4 M8.4 M
Slightly volatile
Property Plant And Equipment Net22.3 M21.3 M9.1 M
Slightly volatile
Accounts Payable1.6 M1.5 M1.2 M
Slightly volatile
Cash82.8 M157.1 M76.7 M
Slightly volatile
Non Current Assets Total16.5 M22.8 M14.7 M
Slightly volatile
Cash And Short Term Investments377.2 M359.3 M130.2 M
Slightly volatile
Net Receivables415.7 K745.2 K513.6 K
Slightly volatile
Common Stock Shares Outstanding23.1 M20.2 M20.5 M
Slightly volatile
Liabilities And Stockholders Equity405.4 M386.1 M146.8 M
Slightly volatile
Non Current Liabilities Total18.1 M11.7 M15.3 M
Pretty Stable
Other Current Assets3.5 M3.3 M1.2 M
Slightly volatile
Total Liabilities26.5 M29.2 M23.2 M
Slightly volatile
Total Current Assets381.5 M363.3 M131.7 M
Slightly volatile
Intangible Assets237.9 K147.2 K294.7 K
Very volatile
Common Stock85590095.1 K
Slightly volatile
Short and Long Term Debt Total15 M14.3 M5.4 M
Slightly volatile
Other Assets0.80.90.9824
Slightly volatile
Short Term Investments212.3 M202.2 M66.4 M
Slightly volatile
Short Term Debt3.6 M3.4 M1.2 M
Slightly volatile
Current Deferred Revenue20.2 M19.3 M7.7 M
Slightly volatile
Capital Lease Obligations11.1 M16.4 M7.4 M
Slightly volatile
Inventory1.2 M1.3 M1.7 M
Slightly volatile
Property Plant And Equipment Gross32.1 M34.1 M29.6 M
Slightly volatile
Net Working Capital363.2 M345.9 M119 M
Slightly volatile
Non Current Liabilities Other43.6 K45.9 K175.4 K
Slightly volatile

Neurogene Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses100.9 M96.1 M42.8 M
Slightly volatile
Research Development73.6 M70.1 M31.2 M
Slightly volatile
Cost Of Revenue6 M3.7 M3.9 M
Slightly volatile
Total Operating Expenses96.9 M92.3 M39.2 M
Slightly volatile
Net Interest Income10.2 M9.7 M1.9 M
Slightly volatile
Interest Income10.2 M9.7 M1.9 M
Slightly volatile
Selling General Administrative14 M26 M10.7 M
Slightly volatile
Reconciled Depreciation2.9 M3.7 M1.6 M
Slightly volatile

Neurogene Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation3.9 M3.7 M1.3 M
Slightly volatile
Capital Expenditures882.7 K929.2 K1.7 M
Pretty Stable
Total Cash From Financing Activities222.3 M211.7 M74.2 M
Slightly volatile
End Period Cash Flow82.9 M157.5 M76.7 M
Slightly volatile
Begin Period Cash Flow179.6 M171 M69.3 M
Slightly volatile
Stock Based Compensation10 M9.6 M2.4 M
Slightly volatile
Issuance Of Capital Stock109.8 M218 M75.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio410391222
Slightly volatile
Days Sales Outstanding205230251
Slightly volatile
Average Payables368 K600.3 K572.4 K
Slightly volatile
Stock Based Compensation To Revenue7.198.18.8358
Slightly volatile
Capex To Depreciation0.210.222.1824
Pretty Stable
EV To Sales135270150
Slightly volatile
Inventory Turnover17.6719.8821.7027
Slightly volatile
Days Of Inventory On Hand13.2214.8716.2297
Slightly volatile
Payables Turnover1.542.191.4261
Slightly volatile
Sales General And Administrative To Revenue19.5622.024.0151
Slightly volatile
Research And Ddevelopement To Revenue62.2359.2731.0848
Slightly volatile
Capex To Revenue0.830.790.4046
Slightly volatile
Cash Per Share16.8116.016.7125
Slightly volatile
Days Payables Outstanding1641731 K
Slightly volatile
Income Quality0.80.850.9773
Pretty Stable
Intangibles To Total Assets0.00140.00140.0054
Slightly volatile
Net Debt To EBITDA1.651.551.9344
Pretty Stable
Current Ratio11.8618.7614.9204
Pretty Stable
Receivables Turnover1.141.281.4019
Slightly volatile
Capex Per Share0.04220.04140.0487
Slightly volatile
Average Receivables17.5 K18.4 K37.8 K
Slightly volatile
Revenue Per Share0.05750.06060.5883
Slightly volatile
Interest Debt Per Share0.670.640.3098
Slightly volatile
Debt To Assets0.02170.03330.0292
Pretty Stable
Operating Cycle24223084.5355
Slightly volatile
Days Of Payables Outstanding1641731 K
Slightly volatile
Ebt Per Ebit1.221.051.1077
Very volatile
Long Term Debt To Capitalization0.00120.00130.0099
Slightly volatile
Quick Ratio11.8418.7614.9089
Pretty Stable
Net Income Per E B T0.80.890.9748
Slightly volatile
Cash Ratio9.478.1111.6811
Very volatile
Days Of Inventory Outstanding13.2214.8716.2297
Slightly volatile
Days Of Sales Outstanding205230251
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.840.911.0243
Very volatile
Fixed Asset Turnover0.05460.057533.1125
Slightly volatile
Debt Ratio0.02170.03330.0292
Pretty Stable
Price Sales Ratio410391222
Slightly volatile
Asset Turnover0.0030.00320.1719
Slightly volatile

Neurogene Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap438.7 M461.8 M2.3 B
Slightly volatile
Enterprise Value303.1 M319 M2.3 B
Slightly volatile

Neurogene Fundamental Market Drivers

Neurogene Upcoming Events

19th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
19th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Neurogene Financial Statements

Neurogene stakeholders use historical fundamental indicators, such as Neurogene's revenue or net income, to determine how well the company is positioned to perform in the future. Although Neurogene investors may analyze each financial statement separately, they are all interrelated. For example, changes in Neurogene's assets and liabilities are reflected in the revenues and expenses on Neurogene's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Neurogene. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue19.3 M20.2 M
Cost Of Revenue3.7 M6 M
Total Revenue832.5 K790.9 K
Stock Based Compensation To Revenue 8.10  7.19 
Sales General And Administrative To Revenue 22.00  19.56 
Research And Ddevelopement To Revenue 59.27  62.23 
Capex To Revenue 0.79  0.83 
Revenue Per Share 0.06  0.06 
Ebit Per Revenue(102.70)(97.56)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
GMGeneral Motors
GMGeneral Motors
CCitigroup
When determining whether Neurogene is a strong investment it is important to analyze Neurogene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neurogene's future performance. For an informed investment choice regarding Neurogene Stock, refer to the following important reports:
How To Invest In Neurogene
Details
Is Neurogene Stock a good investment?
Details
What is Neurogene's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Neurogene Correlation against competitors.
For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurogene. If investors know Neurogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.10)
Return On Assets
(0.27)
Return On Equity
(0.42)
The market value of Neurogene is measured differently than its book value, which is the value of Neurogene that is recorded on the company's balance sheet. Investors also form their own opinion of Neurogene's value that differs from its market value or its book value, called intrinsic value, which is Neurogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurogene's market value can be influenced by many factors that don't directly affect Neurogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Neurogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY